Company

The United Bio-Technology (Hengqin) Co.

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 8, 2026 · PHASE 3 TRIAL

UBT251 Injection Phase Ⅲ Study (OSA-PAP)

ClinicalTrials.gov

This is a Phase 3 trial registration with no posted results; the study is not yet recruiting and outcome data are not available in this registry record.

PreliminaryObesity Obstructive Sleep Apnea NCT07806851

Reported

Planned sample size150

Primary outcome measureChange from baseline in Apnea-Hypopnea Inde…

Treatment duration52 weeks

AUG 17, 2026 · PHASE 3 TRIAL

Phase III Trial of UBT251 in Moderate-to-Severe OSA With Obesity: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.

ClinicalTrials.gov

This is a planned Phase 3 trial with no results reported; the registry record describes the protocol and planned endpoints only, not outcomes.

PreliminaryNCT07767942 Obstructive Sleep Apnea, Obesity UBT251

Reported

Planned enrollment150

PhasePhase 3

Primary outcome measureChange from baseline in Apnea-Hypopnea Inde…